Synthetic Biologics - Microbiome Times Magazine

Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease

June 5, 2018 Microbiome Times

Synlogic, Inc. (Nasdaq: SYBX), announced that new preclinical data from SYNB1020, a Synthetic Biotic medicine currently being evaluated in an ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia, were presented at Digestive […]

Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results

February 22, 2018 Microbiome Times

Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided a clinical programs update and reported financial results for […]